E11.3532

Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye

Risk-adjusting (HCC)Billable code

HCC risk adjustment mapping

CMS-HCC V28

HCC37

Diabetes with Chronic Complications

HCC298

Severe Diabetic Eye Disease, Retinal Vein Occlusion, and Vitreous Hemorrhage

CMS-HCC ESRD V24

HCC18

Diabetes with Chronic Complications

HCC122

Proliferative Diabetic Retinopathy and Vitreous Hemorrhage

RxHCC V08

RXHCC30

Diabetes with Complications

Coding notes

Excludes 1 never coded together · Excludes 2 may co-exist

Inherited from E11.35Type 2 diabetes w proliferative diabetic retinopathy
7th character

One of the following 7th characters is to be assigned to codes in subcategory E11.35 to designate laterality of the disease:

Valid 7th characters and their meanings
CharacterMeaning
1right eye
2left eye
3bilateral
9unspecified eye
Inherited from E11Type 2 diabetes mellitus
Includes

diabetes (mellitus) due to insulin secretory defect diabetes NOS insulin resistant diabetes (mellitus)

Excludes 1

diabetes mellitus due to underlying condition (E08.-) drug or chemical induced diabetes mellitus (E09.-) gestational diabetes (O24.4-) neonatal diabetes mellitus (P70.2) postpancreatectomy diabetes mellitus (E13.-) postprocedural diabetes mellitus (E13.-) secondary diabetes mellitus NEC (E13.-) type 1 diabetes mellitus (E10.-)

Use additional

code to identify control using: injectable non-insulin antidiabetic drugs (Z79.85) insulin (Z79.4) oral antidiabetic drugs (Z79.84) oral hypoglycemic drugs (Z79.84)

Inherited from chapter 4Endocrine, nutritional and metabolic diseases
Excludes 1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)

Note

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.

Official Guidelines for E11.3532

FY 2026 ›